- Home
- MTN vs MIRM Comparison
MTN vs MIRM Comparison
Compare MTN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- MIRM
- Stock Information
- Founded
- MTN 1997
- MIRM 2018
- Country
- MTN United States
- MIRM United States
- Employees
- MTN N/A
- MIRM N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- MIRM Health Care
- Exchange
- MTN Nasdaq
- MIRM Nasdaq
- Market Cap
- MTN N/A
- MIRM 1.9B
- IPO Year
- MTN 1997
- MIRM 2019
- Fundamental
- Price
- MTN $142.00
- MIRM $42.54
- Analyst Decision
- MTN Hold
- MIRM Strong Buy
- Analyst Count
- MTN 10
- MIRM 11
- Target Price
- MTN $190.00
- MIRM $58.55
- AVG Volume (30 Days)
- MTN 719.8K
- MIRM 437.9K
- Earning Date
- MTN 06-05-2025
- MIRM 05-12-2025
- Dividend Yield
- MTN 6.27%
- MIRM N/A
- EPS Growth
- MTN 10.73
- MIRM N/A
- EPS
- MTN 6.89
- MIRM N/A
- Revenue
- MTN $2,946,168,000.00
- MIRM $336,888,000.00
- Revenue This Year
- MTN $4.64
- MIRM $29.51
- Revenue Next Year
- MTN $4.21
- MIRM $20.27
- P/E Ratio
- MTN $20.56
- MIRM N/A
- Revenue Growth
- MTN 3.57
- MIRM 80.76
- 52 Week Low
- MTN $129.85
- MIRM $23.83
- 52 Week High
- MTN $206.38
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- MTN 45.16
- MIRM 53.41
- Support Level
- MTN $134.98
- MIRM $38.22
- Resistance Level
- MTN $142.30
- MIRM $39.87
- Average True Range (ATR)
- MTN 5.68
- MIRM 1.92
- MACD
- MTN 0.83
- MIRM 0.49
- Stochastic Oscillator
- MTN 77.44
- MIRM 93.09
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.